REPLIMUNE GROUP INC. - COMMON STOCK

Replimune Presents Initial RP1 Data from the ARTACUS Clinical Trial at the 2023 American Transplant Congress (ATC) Meeting

06 июн 2023 09:00:00 Источник Nasdaq GlobeNewswire

Replimune Appoints Veleka R. Peeples-Dyer to its Board of Directors

05 июн 2023 07:00:00 Источник Nasdaq GlobeNewswire

Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

03 июн 2023 13:15:00 Источник Nasdaq GlobeNewswire

Replimune to Present at the Jefferies Global Healthcare Conference

01 июн 2023 15:01:00 Источник Nasdaq GlobeNewswire

Replimune to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

25 май 2023 16:00:00 Источник Nasdaq GlobeNewswire

Replimune Reports Fiscal Fourth Quarter and Year Ended 2023 Financial Results and Provides Corporate Update

18 май 2023 07:00:00 Источник Nasdaq GlobeNewswire

Replimune to Participate in the Piper Sandler Spring Biopharma Symposium

09 май 2023 07:00:01 Источник Nasdaq GlobeNewswire

Replimune to Present at Two Upcoming Investor Conferences

08 мар 2023 07:00:01 Источник Nasdaq GlobeNewswire

Replimune Reports Fiscal Third Quarter Financial Results and Provides Corporate Update

09 фев 2023 07:00:01 Источник Nasdaq GlobeNewswire

Replimune to Present at the Virtual SVB Securities Global Biopharma Conference

07 фев 2023 07:00:02 Источник Nasdaq GlobeNewswire

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 янв 2023 07:05:00 Источник Nasdaq GlobeNewswire

Replimune Appoints Former Sanofi U.S. Commercial Oncology Head, Chris Sarchi, as Chief Commercial Officer and Sushil Patel as Chief Strategy Officer

04 янв 2023 07:00:01 Источник Nasdaq GlobeNewswire

Replimune to Present at the 41st Annual J.P. Morgan Healthcare Conference

03 янв 2023 07:00:01 Источник Nasdaq GlobeNewswire

Replimune Announces Pricing of Public Offering

08 дек 2022 20:04:34 Источник Nasdaq GlobeNewswire

Replimune Announces Proposed Public Offering

07 дек 2022 15:04:04 Источник Nasdaq GlobeNewswire

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

07 дек 2022 06:00:00 Источник Nasdaq GlobeNewswire

Replimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 In Colorectal Cancer and Hepatocellular Carcinoma

07 дек 2022 05:30:00 Источник Nasdaq GlobeNewswire

Replimune to Present at the Piper Sandler 34th Annual Healthcare Conference

23 ноя 2022 07:00:00 Источник Nasdaq GlobeNewswire

Replimune to Host Virtual Investor Event on December 7, 2022

22 ноя 2022 07:00:01 Источник Nasdaq GlobeNewswire

Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update

03 ноя 2022 07:00:03 Источник Nasdaq GlobeNewswire